Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CDC25B | P30305 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308273 | 0.82 | HTR6 (0.40) | MAOACES1BCHEALDH1A1SMN1; SMN2 | |
| SCHEMBL27596873 | 0.80 | HTR6 (0.39) | MAOACES1BCHEALDH1A1SMN1; SMN2 | |
| SCHEMBL3684627 | 0.80 | HTR6 (0.39) | MAOACES1BCHEALDH1A1SMN1; SMN2 | |
| Lithium SCHEMBL3684629 | 0.80 | HTR6 (0.39) | MAOACES1BCHEALDH1A1SMN1; SMN2 | |
| SCHEMBL787473 | 0.77 | MEN1 (0.37) | MAOACES1ALDH1A1MEN1KMT2A | |
| SCHEMBL8344964 | 0.76 | METAP1 (0.53) | MAOAALDH1A1SMN1; SMN2MAOBACHE | |
| SCHEMBL6552234 | 0.75 | CES1 (0.56) | MAOACES1BCHEALDH1A1MEN1 | |
| SCHEMBL9321655 | 0.75 | MAOA (0.50) | MAOACES1BCHEALDH1A1MEN1 | |
| SCHEMBL14054414 | 0.75 | MAOA (0.50) | MAOACES1BCHEALDH1A1MEN1 | |
| SCHEMBL2566227 | 0.75 | CES1 (0.50) | MAOACES1BCHEALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222308-A1 | N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NeuroSearch AS (DK) | 2010-09-01 | — | — | EP | claimed |
| EP-2212285-A1 | N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NeuroSearch A/S (DK) | 2010-08-04 | — | — | EP | claimed |
| WO-2009065854-A1 | N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2009-05-28 | — | — | WO | claimed |
| WO-2009065850-A1 | N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2009-05-28 | — | — | WO | claimed |
| US-20140221405-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8101649-B2 | N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2012-01-24 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20100280034-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20070197492-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070196340-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070093534-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-04-26 | — | — | US | disclosed |
| US-20070093534-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-04-26 | — | — | US | disclosed |
| EP-0381290-B1 | Use of a fungicidal composition for the curative treatment of fungal diseases in plants | SHELL INT RESEARCH (NL) | 1995-05-03 | — | — | EP | disclosed |
| US-5304376-A | Acrylic acid morpholide compound dispersed in polymer having melting point below degradation temperature of polymer | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1994-04-19 | — | — | US | disclosed |
| EP-0381290-A2 | Use of a fungicidal composition for the curative treatment of fungal diseases in plants | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1990-08-08 | — | — | EP | disclosed |
| EP-0247513-A1 | Process for producing 2-methyl-1,4-naphthoquinone | Eisai Chemical Co., Ltd. (JP) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197492-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | MAOA 976/4885CES1 3118/4885BCHE 2787/4885 |
| US-20070093534-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | MAOA 3136/4885CES1 1689/4885BCHE 2540/4885 |
| US-20110105597-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | MAOA 1119/4885CES1 1693/4885BCHE 3391/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | MAOA 3785/4885CES1 1296/4885BCHE 3843/4885 |
| US-20100280034-A1 | Modulation of pathogenicity | NR1H4, NR1I3, NR1H2 | MAOA 3136/4885CES1 1689/4885BCHE 2540/4885 |
| US-20140221405-A1 | PLATELET ADP RECEPTOR INHIBITORS | PTAFR, ADGRF1, P2RY6 | MAOA 3054/4885CES1 2363/4885BCHE 4038/4885 |
| US-20070196340-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | MAOA 3136/4885CES1 1689/4885BCHE 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.